tiletamine hydrochloride has been researched along with Retinitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishida, S; Iwabuchi, K; Iwata, D; Kitaichi, N; Miyazaki, A; Namba, K; Ohno, S; Onoé, K; Ozaki, M; Todo, S; Umezawa, K; Yamashita, K; Yoshida, K | 1 |
| Inoue, M; Ishida, S; Izumi-Nagai, K; Koto, T; Nagai, N; Oike, Y; Ozawa, Y; Satofuka, S; Tsubota, K; Umezawa, K; Yamashiro, K | 1 |
2 other study(ies) available for tiletamine hydrochloride and Retinitis
| Article | Year |
|---|---|
Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Topics: Animals; Antigen-Presenting Cells; Autoimmune Diseases; Benzamides; Cell Nucleus; Cyclohexanones; Cytokines; Disease Models, Animal; Down-Regulation; Female; Fluorescent Antibody Technique, Indirect; Injections, Intraperitoneal; Lymphocyte Activation; Mice; Microscopy, Confocal; Retina; Retinitis; T-Lymphocytes; Transcription Factor RelA; Uveitis | 2010 |
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzamides; Blotting, Western; Cell Adhesion; Chemokine CCL2; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Imidazoles; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Pyridines; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidines; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |